Literature DB >> 4052138

Absorption, distribution, excretion and metabolism of orally administered 14C-beta-cyclodextrin in rat.

A Gerlóczy, A Fónagy, P Keresztes, L Perlaky, J Szejtli.   

Abstract

The absorption, distribution, excretion and metabolism of orally administered universally labelled 14C-beta-cyclodextrin and 14C-glucose were compared in rat. The maximum radioactivity of the blood derived from 14C-beta-cyclodextrin was observed between 4th and 11th h and the value of the maximum in different experiments ranged between 5 and 17 0/00 of the total administered radioactivity. Following 14C-glucose treatment radioactivity reached the maximum within half-an-hour, with values of 15 to 82 0/00. In the 8th h after a high dose (313.5 mg/kg) of beta-cyclodextrin no more than 3-50 ppm beta-cyclodextrin was detectable in the blood by HPLC. After 14C-beta-cyclodextrin treatment 4.2-4.8% of the administered total radioactivity was excreted by the urine and about the same quantity (2-3.6%) in case of 14C-glucose. No specific accumulation was observed after 14C-beta-cyclodextrin treatment in the different organs. The large intestine contained 10-15% of the cyclodextrin radioactivity while this value was only 2% in case of 14C-glucose. Following p.o. administration of different doses of 14C-beta-cyclodextrin the radioactivity peak was detected in the exhaled air between the 4-6th and 6-8th h, respectively, depending on the administered doses, while in case of 14C-glucose treatment it was observed within 2 h. The total radioactivity exhaled by 14C-beta-cyclodextrin treated animals in 24 h was 55 to 64% of the administered radioactivity and 58% in case of 14C-glucose. It is assumed that beta-cyclodextrin is metabolized in rats slower but similarly to glucose, therefore p.o. administered beta-cyclodextrin cannot induce toxic symptoms.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4052138

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  7 in total

Review 1.  Colonic drug delivery: prodrug approach.

Authors:  V R Sinha; R Kumria
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

2.  The pharmacokinetics of beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin in the rat.

Authors:  H W Frijlink; J Visser; N R Hefting; R Oosting; D K Meijer; C F Lerk
Journal:  Pharm Res       Date:  1990-12       Impact factor: 4.200

Review 3.  Cyclodextrins: their future in drug formulation and delivery.

Authors:  V J Stella; R A Rajewski
Journal:  Pharm Res       Date:  1997-05       Impact factor: 4.200

4.  Hypolipidemic effects of beta-cyclodextrin in the hamster and in the genetically hypercholesterolemic Rico rat.

Authors:  M Riottot; P Olivier; A Huet; J J Caboche; M Parquet; J Khallou; C Lutton
Journal:  Lipids       Date:  1993-03       Impact factor: 1.880

Review 5.  Piroxicam-beta-cyclodextrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in rheumatic diseases and pain states.

Authors:  C R Lee; J A Balfour
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

6.  Studies of the Formation and Stability of Ezetimibe-Cyclodextrin Inclusion Complexes.

Authors:  Marta Biernacka; Tatsiana Ilyich; Ilya Zavodnik; Bartłomiej Pałecz; Artur Stepniak
Journal:  Int J Mol Sci       Date:  2021-12-31       Impact factor: 5.923

Review 7.  Piroxicam-β-cyclodextrin: a GI safer piroxicam.

Authors:  C Scarpignato
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.